You worked through a structured protocol, hit your goal, and now the harder question arrives: how do you hold the line without rigid, full-dose autopilot? If you think in systems, "maintenance" deserves the same rigor your loss phase got.
This article is educational and is not medical advice. Any decision about starting, continuing, lowering, or stopping a medication is made between you and an independent licensed provider.
Why "maintenance" is its own goal, not an afterthought
The anxiety about regain is well-founded, not paranoia. In the STEP 1 extension trial, participants who stopped semaglutide regained a substantial share of the weight they had lost within roughly a year, and several cardiometabolic markers drifted back toward baseline [1]. The SURMOUNT-4 trial on tirzepatide showed a similar pattern: continued treatment was associated with maintained weight, while switching to placebo was associated with regain [2]. The mechanism is unsurprising. GLP-1 and GIP receptor agonists work largely by modulating appetite signaling and gastric emptying; remove the signal and the underlying physiology that drove weight gain in the first place reasserts itself [3].
The practical takeaway is that maintenance is a distinct phase with its own logic. The loss phase asks "how much change can we drive?" The maintenance phase asks "what is the least intervention that holds the result while protecting metabolic health?" Those are different questions, and they deserve different conversations.
Source: [1] Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, [2] Effect of Continued Weekly Subcutaneous Tirzepatide vs Placebo on Weight Maintenance (SURMOUNT-4)
What "microdosing" actually refers to
First, a precise definition, because the word is used loosely. In the GLP-1 context, "microdosing" colloquially refers to using a lower amount of medication than a standard therapeutic target dose—often as a maintenance strategy after a goal is reached. It is not a recognized, standardized clinical term, and there is no established, trial-validated "maintenance microdose" the way there are studied titration targets for the loss phase. That gap matters: it means a thoughtful provider is reasoning from physiology and your individual data, not reading off a published maintenance ladder.
This is exactly where a fixed-dose protocol and a partnership diverge. A script-filler offers one ladder up and the same ladder down. A provider engaged with maintenance treats the dose as one variable among several, adjusted against how your body and labs respond over time. No article can tell you a specific amount—dosing is the provider's role, individualized to you—but you can understand the framework they reason within.
If a compounded formulation enters the conversation, an important disclosure applies: compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state. The FDA has also noted specific concerns about dosing errors with compounded GLP-1 products, which is one more reason this phase belongs under provider supervision rather than self-management [4].
Source: [3] Glucagon-like peptide-1 receptor agonists (GLP-1 RAs): mechanisms and clinical use (review), [8] National Weight Control Registry: long-term weight maintenance findings
The biomarkers a provider keeps watching
Maintenance is where lab-guided thinking earns its keep, because the goal shifts from a number on a scale to durable metabolic health. A provider partnering on maintenance typically keeps an eye on several domains over time.
Glucose and insulin sensitivity. Hemoglobin A1c reflects average blood glucose over roughly three months; the ADA defines diagnostic thresholds at 5.7–6.4% for prediabetes and 6.5% or higher for diabetes [5]. Watching A1c (alongside fasting glucose) over a maintenance window tells a provider whether glycemic gains are holding or slipping.
Lipids. Cardiometabolic risk is a core reason many people pursue and protect weight loss in the first place. Standard lipid panels—LDL cholesterol, HDL, triglycerides—are tracked against guideline-based risk frameworks from the American College of Cardiology and American Heart Association [6].
Body composition, not just body weight. Rapid or sustained weight loss can include lean mass, and protecting muscle is central to staying metabolically sharp into your 50s [7]. A provider may track weight trend, waist circumference, and—where available—body-composition measures, because holding goal weight while losing muscle is not the win it appears to be.
Tolerability and safety signals. Beyond efficacy markers, providers monitor for known class effects and gastrointestinal tolerability, and review symptoms at each visit [3]. The point of regular review is to catch drift early—when small adjustments are easiest.
% A1c · marker = Diabetes threshold
Source: [5] American Diabetes Association: Classification and Diagnosis of Diabetes (Standards of Care)
Why adherence and lifestyle still carry the work
Here is the part the optimizer in you already suspects: the medication is a tool that makes the behavioral work feasible, not a substitute for it. Protein-forward nutrition and resistance training are the most direct levers for protecting lean mass during and after weight loss, and physical activity is consistently associated with weight-maintenance success in long-term observational data [7][8]. Sleep and stress feed appetite-regulating pathways too. A lower-dose maintenance strategy, if a provider deems it appropriate, leans more heavily on these foundations—which is precisely why maintenance is a partnership, not a refill.
Think of it as a system with redundancy: when the pharmacological signal is dialed back, the lifestyle infrastructure has to carry more of the load. That is not a downside; for someone who wants the least intervention that holds the line, it is the design goal.
What a good maintenance conversation sounds like
A provider engaged with maintenance will want your history, your current labs, your goals, and your tolerances—then reason transparently about trade-offs. They should be able to explain why they're tracking a given marker, what a change would prompt, and how they'd adjust. They will also be honest about the limits of the evidence: that long-term, low-dose maintenance protocols are an area of active study rather than settled science, and that a prescription is never guaranteed—it's a clinical decision made by an independent licensed provider.
What you're looking for is not a doctor who hands you a smaller number, but one who treats your maintenance phase as a measurable, adjustable system you build together.
Where Velri fits
Velri is a technology and coordination company—not a medical practice. We help organize the moving parts of a maintenance-phase conversation: coordinating lab work, connecting you with an independent licensed provider for an evaluation, and, if that provider determines a treatment is appropriate and writes a prescription, coordinating with an independent licensed pharmacy. Velri does not provide medical care, does not prescribe, and cannot guarantee any specific treatment or outcome. The clinical decisions—including whether any medication is appropriate and at what dose—rest entirely with the independent provider, informed by your labs and history. This article is educational and not a substitute for personalized medical advice.
